Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fanregratinib in Advanced Solid Malignancies
NCT02966171Phase 1Terminated
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fanregratinib in solid tumor, sponsored by Hutchison MediPharma (HMP). Primary endpoint: Incidence of Dose Limiting Toxicities. Started Jan 2017; status: terminated.
02
Drugs
fanregratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02966171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966171.